Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 62

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Plasma cell myeloma

Not recruiting

Study on the Safety and Tolerability of OsteoDex for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Osteodex

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Study on Long-Term Safety of INBRX-101 for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human ALPHA-1-PROTEINASE inhibitor immunoglobulin G fusion protein, recombinant

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:SwedenSweden
  • Participants:65+ years
  • Substances:BI 1015550

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Study of sulthiame combined with oral appliance therapy for patients with obstructive sleep apnea who have incomplete response to oral appliance treatment alone

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sultiame
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human ALPHA1-PROTEINASE inhibitor

Study on the Safety and Efficacy of ARGX-119 for Adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG1 monoclonal antibody against muscle specific kinase

Study of spironolactone and eplerenone in patients with heart failure with preserved ejection fraction (HFpEF)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Altizide

Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.